Active Ingredient History
Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation. Gefitinib is used for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 3)
Adenoma (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Astrocytoma (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 2)
Brain Neoplasms (Phase 2/Phase 3)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2/Phase 3)
Drugs, Generic (Phase 1)
Epidermal Growth Factor (Phase 3)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Gastrinoma (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1/Phase 2)
Gliosarcoma (Phase 2)
Glucagonoma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 4)
Healthy Volunteers (Phase 1)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 2)
Mutation (Phase 2/Phase 3)
Nasopharyngeal Carcinoma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Squamous Cell (Phase 2)
Neuroblastoma (Phase 2)
Oligodendroglioma (Phase 1/Phase 2)
Osteosarcoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 1/Phase 2)
Pituitary ACTH Hypersecretion (Phase 2)
Progression-Free Survival (Phase 2)
Prostatic Neoplasms (Phase 2)
Respiratory Tract Diseases (Phase 2)
Respiratory Tract Neoplasms (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 1)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Self Efficacy (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Somatostatinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Thoracic Neoplasms (Phase 3)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Vipoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
